Small Molecule Drug Discovery CRO: How to Choose the Right Partner
Small Molecule Drug Discovery CRO: How to Choose the Right Partner
Meta Description: Learn how to choose the best small molecule drug discovery CRO. Evaluate medicinal chemistry depth, custom synthesis, FTE services, and IP protection. Read more.
Choosing a small molecule CRO is less about headline capacity than about scientific fit. The right partner should combine medicinal chemistry depth, reliable custom synthesis, appropriate engagement models, strong data quality, and a clear path from hit identification to scalable material.
This guide explains how to evaluate these capabilities, where discovery programs commonly stall, and how a paid pilot can help sponsors test a CRO’s chemistry, communication, and operating model before making a larger commitment.
Scientific Fit Depends on the Development Stage
The best CRO is the one whose operating model fits the scientific question and the next development gate.
A hit-identification campaign may need rapid design-make-test-analyze cycles, while a late lead needs tighter control of stereochemistry, impurities, physicochemical properties, and route robustness. Sponsors should therefore look beyond equipment lists and ask how the CRO adapts its team, assays, analytical package, and project governance to different development needs.
Medicinal chemistry capability should also be judged by the quality of each design cycle, not compound throughput alone. A useful partner should be able to balance:
ChemExpress reports more than 150 medicinal chemistry projects completed and more than 90 preclinical candidates delivered since 2020. Its disclosed full-time equivalent (FTE) productivity is about three to seven compounds per scientist per month.
These figures are useful diligence references. The stated scope covers target validation, hit identification, structure-based discovery, lead optimization, preclinical candidate development, and compounds for IND filing, using FTE and fee-for-service models. However, they should be evaluated together with hypothesis quality, assay strategy, and project-specific complexity.
Route Quality Determines Whether Discovery Keeps Moving
Promising compound designs can still stall if the synthesis is difficult, inefficient, or poorly reproducible.
Sponsors should review CRO experience with challenging chemistry such as:
Analytical data should also accompany compound delivery. ChemExpress’s FTE material states that analysis spectra and original proton NMR packages are supplied for target compounds.
Project examples can provide stronger evidence than generic capability claims. In one disclosed ChemExpress program, a published 19-step linear synthesis of heptelidic acid with less than 0.08% overall yield was redesigned to 12 steps with an overall yield of roughly 3–5%, followed by preparation of more than 150 substituted targets. Another project involving colletodiol addressed multiple stereocenters and regioselectivity, evaluated several routes, and delivered more than 100 previously unreported compounds. These results are project-specific and should not be treated as guaranteed outcomes for other molecules.
FTE and FFS Support Different Discovery Models
The engagement model should match how frequently project priorities are expected to change.
FTE (full-time equivalent) chemistry is generally better suited to iterative programs where biological results continuously influence compound design. A dedicated team can redirect chemistry without renegotiating each individual compound.
FFS (fee-for-service) works better when the target, route, material quantity, and data package are clearly defined.
Hybrid models are also common. An FTE team may manage iterative medicinal chemistry while specialist synthesis, purification, or scale-up work is commissioned against defined milestones.
ChemExpress describes a team structure that includes a project leader, team leader, bench chemists, and analytical and purification support, with weekly reports or teleconferences and data-attached delivery.
Technology Platforms Expand Options but Do Not Replace Feasibility
Enabling technologies can broaden the experimental options available to a discovery program. The platform information lists capabilities including:
These ranges indicate platform capability, not automatic suitability for every substrate or hazard class. Feasibility and safe operating limits still require project-specific review.
IP Protection and Quality Require Verifiable Controls
Trust is operational. ChemExpress states that it has no internal medicinal chemistry research programs and uses tiered controls for email, external networks, shared drives, backup, and archival data.
Its website also reports ISO 9001 certification, more than 350 client audits since 2021, five EU third-party QP GMP audits, and one U.S. FDA inspection with zero Form 483 observations. Sponsors should verify which legal entity, site, quality system, and service phase each credential covers before relying on it.
A Paid Pilot Tests CRO Fit Before Full Commitment
A paid pilot or tightly scoped first work package can reveal how a CRO operates under real project constraints.
Sponsors can provide the target product profile, known liabilities, assay turnaround times, acceptable structural space, data standards, and decision rights. The CRO can then be asked to return:
Reviewing one difficult-chemistry example in detail may reveal more than a broad capability presentation.
| Evaluation Dimension | What to Ask | Red Flags | Why It Matters |
|---|---|---|---|
| Medicinal chemistry depth | How does the team balance potency, selectivity, ADME, and safety in each design cycle? | Throughput metrics without hypothesis quality context | Determines whether each cycle produces a decision, not just a compound |
| Custom synthesis capability | Can they handle air-sensitive, high-pressure, regioselective, and multi-step routes? | No examples of route redesign or scale-up failure recovery | Route failures are the leading timeline killer in discovery programs |
| Engagement model (FTE vs. FFS) | Is the team structured for iterative learning or fixed deliverables? | Rigid contracts that cannot redirect with biology data | FTE supports design-make-test cycles; FFS suits defined targets and milestones |
| Technology platforms | Which enabling technologies are available (HTE, flow, photochemistry, biocatalysis)? | Platform list without a project-specific feasibility process | Expands experimental options but does not guarantee faster routes |
| IP protection and quality | What data controls, audits, and certifications does the site hold? | No ISO certification, no audit history, no IP firewall | Protects sponsor assets and ensures regulatory-grade data traceability |
| Communication governance | What is the weekly cadence, escalation path, and decision rights? | No structured reporting format or named single point of contact | Prevents silent drift and misaligned priorities |
ChemExpress Combines Discovery Chemistry with Scale-Up Support
ChemExpress offers an integrated small-molecule platform for programs that need continuity from design through scale-up. Its stated capabilities include medicinal chemistry, custom synthesis from milligram to kilogram scale, process development, analytical support, and access to enabling technologies such as HTE, photochemistry, biocatalysis, flow chemistry, and preparative chromatography.
Its operating model also combines tiered data controls, ISO 9001 certification, and a history of client and regulatory audits. These capabilities can reduce handoffs when the project requires continuity across medicinal chemistry, synthetic chemistry, analytical support, and later-stage development. However, company-reported metrics should remain a starting point for diligence rather than a guarantee.
Conclusion
Choosing a small molecule drug discovery CRO is ultimately a scientific and operational decision. Sponsors should look for chemistry depth, route quality, an engagement model that fits the program, verifiable IP and quality controls, and an operating model that can be tested in practice.
A scoped paid pilot can help confirm whether those capabilities translate into reliable communication, data quality, and problem solving before the relationship expands. If you are evaluating options for a small molecule drug discovery program, ChemExpress can help assess how an integrated medicinal and synthetic chemistry platform may reduce handoffs across discovery and scale-up.
FAQ
Q1: What questions should I ask a small molecule drug discovery CRO before signing a contract?
A: Ask for a project-specific team chart, relevant route examples, design and assay decision rules, raw-data standards, expected cycle time, IP controls, and an escalation process. Verify site-level quality credentials and define acceptance criteria for identity, purity, quantity, and documentation before work begins.
Q2: Is FTE or FFS better for medicinal chemistry at a CRO?
A: FTE is usually better for iterative programs where targets and priorities change with biological data. FFS suits discrete compounds, fixed routes, or milestone-based packages. A hybrid can keep design-make-test cycles flexible while assigning specialist synthesis, purification, or scale-up to defined deliverables.
Q3: How many compounds should one FTE chemist produce per month at a drug discovery CRO?
A: There is no universal number. Complexity, route length, purification, analytical requirements, and failure rate all matter. ChemExpress reports about three to seven compounds per FTE scientist per month across its experience. Treat that as a diligence reference, then agree on project-specific capacity and learning goals.
Q4: Can a single CRO handle both drug discovery synthesis and process development?
A: Yes, if the organization has both functions and a controlled handoff. ChemExpress describes support from medicinal and synthetic chemistry through route optimization, safety evaluation, non-GMP or GMP scale-up, and process validation. Confirm the receiving site, documentation package, and quality responsibilities for your phase.
Q5: Do HTE, flow chemistry, and biocatalysis guarantee faster drug discovery routes?
A: No. These platforms expand the experimental options, but substrate behavior, hazard, equipment fit, and downstream isolation determine value. Request a feasibility review with measurable decision points. ChemExpress lists all three platforms, along with photochemistry and preparative chromatography, for project-specific deployment.
References
1. U.S. Food and Drug Administration. "The Drug Development Process."
2. Sun, D. et al. "Why 90% of clinical drug development fails and how to improve it." Nature Reviews Drug Discovery, 2024.
3. NIH SEED. "Regulatory Knowledge Guide for Small Molecules." 2024.
4. ChemExpress. Company-reported operating metrics (as of 2026). ISO 9001 certification; client and regulatory audit history.